Roche has been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally.
They were one of the first companies to bring targeted treatments to patients. With their combined strength in pharmaceuticals and diagnostics, they are well equipped to further drive personalised healthcare. Two-thirds of their Research and Development projects are being developed with companion diagnostics.
They are the world’s number 1 in biotech with 17 biopharmaceuticals on the market. Over half of the compounds in their product pipeline are biopharmaceuticals, enabling them to deliver better-targeted therapies.
Roche has been at the forefront of cancer research and treatment for over 50 years, with medicines for breast, skin, colon, ovarian, lung and numerous other cancers.
They offer doctors profound information to guide treatments and to answer more patients’ questions than any other company. And their tests enable hospitals and labs to deliver that information quickly and reliably.
Roche invests around 9 billion Swiss francs in Research and Development every year because innovation is their lifeblood. This is amongst the highest Research and Development spends in the world across all industries.
They are a force of over 90,000 people working together across more than 100 countries. Roche is consistently ranked as an employer of choice by its employees and by external institutions.
For many years running, they have been recognized by the Dow Jones Sustainability Indices as the leader in sustainability within their industry.
Roche and NCIMI
They have partnered with NCIMI (National Consortium of Intelligent Medical Imaging) to investigate the role that AI can play in medical imaging.
To learn more about Roche please visit their website.
No related projects found